Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

19.73 -0.37 (-1.84%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) ↗

July 18, 2025

Via Benzinga

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

July 15, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗

July 02, 2025

Via Benzinga

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)

July 01, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Apellis Pharmaceuticals's Earnings Outlook ↗

May 06, 2025

Via Benzinga

Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views ↗

March 03, 2025

Via Benzinga

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

June 06, 2025

From Apellis Pharmaceuticals, Inc.; Sobi

Via GlobeNewswire

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 04, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts ↗

May 22, 2025

Via Benzinga

Why Apellis Pharmaceuticals Wilted on Wednesday ↗

May 07, 2025

Via The Motley Fool

Topics Earnings

What 6 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗

February 13, 2025

Via Benzinga

Analyst Expectations For Apellis Pharmaceuticals's Future ↗

January 21, 2025

Via Benzinga

Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

May 07, 2025

Via Benzinga

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

May 07, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

May 06, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

April 30, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗

April 29, 2025

Via Benzinga

Apellis Announces Craig Wheeler to Join the Board of Directors

April 21, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals ↗

April 01, 2025

Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.

Via Benzinga

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

April 01, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre ↗

March 18, 2025

JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with over 94,000 doses delivered.

Via Benzinga

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst ↗

March 05, 2025

JP Morgan sees Apellis' Syfovre as a potential $1.5B drug. Empaveli's approval for C3G/IC-MPGN could drive stock growth with a U.S. launch in 2H 2025.

Via Benzinga

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

February 28, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For February 28, 2025 ↗

February 28, 2025

Via Benzinga

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

February 24, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

February 20, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

February 14, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 04, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

January 27, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

All News about Apellis Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today